Pediatric HIV Infection Clinical Trial
Official title:
Evaluating an HIV Risk Screening Tool for Use in a Population of Orphans and Other Vulnerable Children in Tanzania
NCT number | NCT04517760 |
Other study ID # | EG0216 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | February 22, 2018 |
Est. completion date | September 30, 2019 |
Verified date | August 2020 |
Source | Elizabeth Glaser Pediatric AIDS Foundation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The goal of the research was to evaluate the performance of items within the Kizazi Kipya (K2) Orphan and Vulnerable Children (OVC) HIV risk screening tool in identifying HIV-positive children, to optimize an HIV screening tool for OVC and children and adolescents in facility settings and to assess the feasibility and acceptability of home-based HIV risk screening and testing.
Status | Completed |
Enrollment | 21080 |
Est. completion date | September 30, 2019 |
Est. primary completion date | September 30, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 19 Years |
Eligibility |
Children and adolescents and their caregivers: Inclusion Criteria: - Living in a household deemed to be at elevated HIV risk based on previously identified risk criteria - Attending a study health facility in two regions of Tanzania - Age 2-19 years Exclusion Criteria: - Previously tested HIV-positive - History of antiretroviral treatment (ART) - Unable or unwilling to be consented - Age 5-19 years old, tested negative in past 6 months, and having no reported exposure to HIV through sexual contact (consensual, abuse) or through blood transfusion/needle injury. Community care workers: Inclusion criteria: - conducting HIV risk screening in OVC households as part of their role in the Kizazi Kipya project in the subset of study districts where structured observations and focus group discussions were conducted Exclusion criteria: - unwilling to consent to the study |
Country | Name | City | State |
---|---|---|---|
Tanzania | Elizabeth Glaser Pediatric AIDS Foundation | Dar es Salaam |
Lead Sponsor | Collaborator |
---|---|
Elizabeth Glaser Pediatric AIDS Foundation | PACT International, Tanzania Ministry of Health, Community Development, Gender, Elderly and Children |
Tanzania,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sensitivity of HIV risk screening tool | Children/adolescents testing HIV positive on the tool who are truly HIV positive | Within four weeks | |
Primary | Specificity of HIV risk screening tool | Children/adolescents testing HIV negative on the tool who are truly HIV negative | Within four weeks | |
Primary | Positive predictive value | Proportion of children/adolescents testing positive on the tool who actually have HIV | Within four weeks | |
Primary | Negative predictive value | Proportion of children/adolescents testing negative on the tool who do not actually have HIV | Within four weeks | |
Primary | Acceptability of HIV risk screening tool | Examining the extent of reception of the screening tool by the OVC caregivers and the community case workers using a semi-structured questionnaire | Within six weeks | |
Primary | Feasibility of HIV risk screening tool | Exploring the practicality of use of HIV risk screening tool through focus group discussions with community case workers | Within six weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06281834 -
Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention
|
Phase 1 | |
Completed |
NCT04206878 -
Evaluating the Feasibility of Point of Care Birth Testing in Eswatini
|
||
Recruiting |
NCT05069688 -
Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin
|
Phase 1 | |
Active, not recruiting |
NCT03024762 -
Active Search for Pediatric HIV/AIDS (ASPA)
|
N/A | |
Recruiting |
NCT05006170 -
Pharmacokinetics, Safety, and Efficacy of Dolutegravir Dispersible Tablets in Young Children Living With HIV
|
Phase 2 | |
Not yet recruiting |
NCT03980119 -
Utilizing the HITSystem for Optimizing Paediatric ART Retention and Adherence in Western Nyanza Province, Kenya
|
N/A | |
Completed |
NCT03824067 -
Impact of Point-of-Care EID for HIV-Exposed Infants
|
N/A |